Intraglandular botulinum neurotoxin (BoNT) injection vs No BoNT (placebo or pre-treatment baseline)
Development of >=1 new carious lesion (caries incidence) · Patients with drooling (sialorrhea) due to neurological disease
In one RCT, BoNT-B 2500 U was not associated with a statistically significant increase in new caries versus placebo (RR 2.4, 95% CI 0.48 to 11.80; not significant).
2 findings from 1 review
- Oral health effects of botulinum toxin treatment for drooling: a systematic review. 2020 All outcomesNeurological-disease populations with drooling (e.g., cerebral palsy, Parkinson disease, adults with sialorrhea); specialist clinical care · BoNT-B 2500 U vs placebo (Isaacson RCT)RR 2.4 [0.48, 11.80]1 studyGRADE not reported
- Oral health effects of botulinum toxin treatment for drooling: a systematic review. 2020 All outcomesNeurological-disease populations with drooling (e.g., cerebral palsy, Parkinson disease, adults with sialorrhea); specialist clinical care · BoNT-B 3500 U vs placebo (Isaacson RCT)RR 1.4 [0.24, 8.12]1 studyGRADE not reported